Health Care/Hospital
GenFleet Therapeutics to Present Data from Phase I Trial of GFH018 Monotherapy at the 2022 European Society for Medical Oncology Annual Meeting
SHANGHAI and PARIS, Sept. 7, 2022 /PRNewswire/ -- GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, today announced the results from phase I study of GFH018 (TGF-β R1 inhibitor) monotherapy (NCT05051241) for treatment of a...
2022-09-07 19:00
2699
Waterdrop Announces Appointment of a New Director
BEIJING, Sept. 7, 2022 /PRNewswire/ -- Waterdrop Inc. ("Waterdrop", the "Company" or "we") (NYSE: WDH), a leading technology platform dedicated to insurance and healthcare service with a positive social impact, today announced the appointment of Ms.Wenjie Guan as a new director to its board of di...
2022-09-07 16:54
2684
Laekna Announces First Patient Dosed in South Korea in LAE201INT2101 Phase 1/2 Study
SHANGHAI and WARREN, N.J., Sept. 6, 2022 /PRNewswire/ -- Laekna, a clinical-stage biotechnology company dedicated to bringing ground-breaking therapies to cancer and liver fibrosis patients worldwide, announced yesterday that the first patient recently received a dose in the LAE201INT2101 phase ...
2022-09-06 17:02
1902
Jacobio Receives CDE Approval for KRAS G12C Inhibitor JAB-218822's Phase II Pivotal Study in China
BEIJING, SHANGHAI and BOSTON, Sept. 6, 2022 /PRNewswire/ -- Jacobio Pharma (1167.HK) has received Phase II pivotal study approval of KRAS G12C inhibitor JAB-21822 from the Center for Drug Evaluation (CDE) ofChina in September 5, 2022 . This study aims to treat advanced or metastatic non-small cell...
2022-09-06 15:20
1785
Dizal Announces Sunvozertinib Meets Primary Endpoint in its First Pivotal Study in Platinum-Pretreated NSCLC Patients with EGFR Exon20ins Mutations at 2022 ESMO
* The confirmed objective response (cORR), as assessed by blinded independent central review (BICR), was 59.8% in advanced NSCLC with EGFR exon20ins mutations after at least one line of platinum-based chemotherapies * The response rate for patients with baseline brain metastasis was 48.4% * ...
2022-09-05 22:49
2561
Dizal Announces Positive Phase I Clinical Trial Results for DZD1516 in Treating HER2 Breast Cancer at 2022 ESMO
PARIS, Sept. 5, 2022 /PRNewswire/ -- Dizal reported the promising safety and pharmacokinetic data from the global Phase I study ofDZD1516 in patients with HER2 positive metastatic breast cancer (HER2+ MBC) who relapsed from multiple prior treatments at the 2022 European Society for Medical Oncolo...
2022-09-05 22:39
2488
Recruitment opens for Phase II trial in prostate cancer with Cu-64 SAR-Bombesin in the US
SYDNEY, Sept. 5, 2022 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to announce that the US-based diagn...
2022-09-05 21:09
2686
Lunit to Showcase 5 Abstracts at ESMO 2022
* Lunit to present five posters at ESMO 2022 featuring the company's AI-biomarker platform * Studies corroborate the capability of Lunit SCOPE suite to address an expanding set of clinical and research questions based on world-leading digital pathology AI SEOUL, South Korea, Sept. 5, 2022 /PR...
2022-09-05 21:00
2670
Vernalis Research, a fully owned subsidiary of HitGen Inc., and Unison Medicines Inc. announce a research collaboration in the field of anti-infectives
CHENGDU, China, Sept. 5, 2022 /PRNewswire/ -- Vernalis Research ("Vernalis"), a fully owned subsidiary of HitGen Inc., and Unison Medicines Inc. ("Unison") are pleased to announce a research collaboration on an undisclosed bacterial target. Under the terms of the agreement, Vernalis will use it...
2022-09-05 16:00
2724
Simcere Pharmaceutical Announces Financial Results for 2022 H1: 27% Year-Over-Year Revenue Growth, with Innovative Drugs Accounting for 65.4% of Total Revenue
NANJING, China, Sept. 5, 2022 /PRNewswire/ -- Simcere Pharmaceutical Group Limited (2096.HK) announced its financial results for the first half of 2022. As ofJune 30, Simcere recorded operating revenue of RMB 2.7 billion for the first half of the year, with a year-over-year growth of 27.3%. The e...
2022-09-05 13:09
3544
Tamas Oravecz Ph.D. named SVP, CSO of the U.S. of Simcere Pharmaceutical Group
NANJING, China, Sept. 5, 2022 /PRNewswire/ -- Simcere Pharmaceutical Group announces today the appointment ofTamas Oravecz, Ph.D. as Senior Vice President, Chief Scientific Officer of the Simcere U.S. Tamas will be responsible for providing strategic leadership to our drug discovery efforts in A...
2022-09-05 13:08
2522
New Building Stands as Symbol of Dignity and Hope For Persons Affected by Leprosy in Ethiopia
TOKYO, Sept. 2, 2022 /PRNewswire/ -- Sasakawa Health Foundation has funded the
construction of a building inAddis Ababa for the Ethiopian National Association
of Persons Affected by Leprosy (ENAPAL).
2022-09-02 22:00
8147
Neukio Biotherapeutics completed Series A-1 financing, to accelerate discovery and development of next generation cell therapy products
SHANGHAI, Sept. 2, 2022 /PRNewswire/ -- Neukio Biotherapeutics, a company committed to developing novel cell therapy products, announces it has closed $50 million in a Series A-1 funding round. The investment round was led by CD Capital, with the participation of Alwin Capital and Surplus Capital...
2022-09-02 20:50
3617
Waterdrop Inc. to Report Second Quarter 2022 Financial Results on September 9, 2022
BEIJING, Sept. 2, 2022 /PRNewswire/ -- Waterdrop Inc. (NYSE: WDH) ("Waterdrop" or the "Company"), a leading technology platform dedicated to insurance and healthcare service with a positive social impact, today announced that it will report its unaudited financial results for the second quarter e...
2022-09-02 20:00
4877
Jacobio Completes First Patient Dosage of CD73 mAb JAB-BX102 in China
BEIJING, Sept. 2, 2022 /PRNewswire/ -- Jacobio Pharma (1167.HK) announced it has completed first patient dosage of it's in-house R&D drug candidate CD73 monoclonal antibody JAB-BX102 in a Phase I/IIa clinical trial for advanced solid tumour patients. This is a phase I/IIa multi-center, open-la...
2022-09-02 19:00
2406
Jacobio Completes First Dose of IIa Clinical Trial of JAB-21822 on KRAS G12C and STK11 Co-mutation in China
BEIJING, Sept. 1, 2022 /PRNewswire/ -- JacobioPharma (1167.HK) announced that the company has dosed the first non-small cell lung cancer (NSCLC) patient with KRAS G12C and STK11 co-mutation in the Phase IIa trial of KRAS G12C inhibitor JAB-21822 inChina. JAB-21822 is a KRAS G12C inhibitor inde...
2022-09-02 17:14
2078
Bridge Biotherapeutics Presented Non-clinical Study Results for 2 IPF Candidates at the IPF Summit 2022
* Non-clinical studies explored the potent anti-fibrotic and anti-inflammatory efficacy of BBT-301 and BBT-209 for IPF treatment * Company enhances its strategic focus on fibrotic diseases inclusive of IPF with 1 clinical asset and 2 non-clinical assets BOSTON and SEONGNAM, South Korea ,Sept. ...
2022-09-02 09:41
1770
Pxierra is launching world's first non-contact heart rate & breathe rate measurement AI baby monitor
NEW YORK, Sept. 1, 2022 /PRNewswire/ -- Pxierra is excited to announce the launch of its innovative AI Baby monitor. This new device is designed to provide non-contact heart rate and breathing rate measurement, making it easier and more convenient for parents to keep track of their newborns' vita...
2022-09-01 21:00
1950
Zhongchao Inc. Announces its New Strategy Extension Focusing on the Oncology and Other Major Disease Management
SHANGHAI, Sept 1, 2022 /PRNewswire/ -- Zhongchao Inc. (NASDAQ: ZCMD) ("Zhongchao" or the "Company"), an internet technology company offering healthcare professionals the online healthcare information, professional training and educational services platform and patient management service, today a...
2022-09-01 19:30
2808
The ECO-Friendly Anti-nausea and Vomiting wristband: Emeterm PLUS
VANCOUVER, BC, Aug. 31, 2022 /PRNewswire/ -- WAT Medical is thrilled to introduce its latest innovative technology that would help the millions of people who suffer from nausea and vomiting, the EmeTerm Plus, while also developing an eco-friendly roadmap that would benefit future innovations. The...
2022-09-01 01:15
1989
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 314 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30
QDX Co-Founder Giuseppe Barca Awarded Prestigious Gordon Bell Prize, Pioneering Advancements in Drug Discovery Technology
[Picked up by 295 media titles]
2024-11-26 18:49Southeast Asian Consumers Raise Online Security Concerns, New GSMA Survey Shows
[Picked up by 293 media titles]
2024-11-26 13:00Most Read
Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
2024-11-20 16:30
9294
Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
2024-11-20 09:00
7762
Chinese path to modernization a model for Global South, experts say
2024-11-23 15:35
7521
